MM-151

MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer[1].

1399724-72-1

12352203

EGFR

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

[1]Arena S, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016 Feb 3;8 (324) :324ra14. |[2]Kearns JD, et al. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer Ther. 2015 Jul;14 (7) :1625-36.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991572/

Inhibitory Antibodies

No Development Reported